At least 4 medtech exits were significant enough to make the cut for the top 20 venture capital-backed healthcare exits of 2014, according to research firm CB Insights.
Initial Public Offering (IPO)
Avinger closes out 2014 with $69m IPO
Avinger closed out a feverish medtech IPO season with by registering for a $69 million initial public offering in the waning days of 2014.
Redwood City, Calif.-based Avinger, which makes a family of vascular catheters aimed at the peripheral vascular market, filed Dec. 30 with the FDA for the offering. The company was founded in 2007.
Check-Cap plans $27m round for low-dose X-ray imaging capsule
Report: BiOM may file for IPO in 2016
Personal bionics maker BiOM may eventually take its case to the public markets, eyeing a potential initial public offering, according to a report in the Boston Business Journal.
BeneChill files for $14m IPO
The red-hot IPO market for medical device companies shows no signs of abating as the year comes to a close, with BeneChill yesterday tossing its hat in the ring for a nearly $14 million flotation.
Infraredx files for $55m IPO
Infraredx yesterday registered for an initial public offering with the Securities & Exchange Commission, estimating the flotation’s worth at $55 million.
Burlington, Mass.-based Infraredx makes an imaging system that combines intravascular ultrasound and near-infrared spectroscopy to provide images of the interior of coronary blood vessels.
Diabetes: Asante Solutions registers for $45m IPO
Asante Solutions registered for a $45 million initial public offering for its modular Snap insulin pump, which is designed to use pre-loaded insulin cartridges.
Year in review: 2014 was the year of the medtech IPO
Second Sight Medical’s IPO grosses $36m
Second Sight CEO Greenberg: Next-gen ‘bionic eye’ could treat nearly all forms of blindness
Eyesight to the blind: Second Sight prices $32m IPO
Second Sight Medical said today that it expects to reap nearly $32 million today when its shares debut on the public market.